Back to Search Start Over

Mutation characteristics of cancer susceptibility genes in Chinese ovarian cancer patients.

Authors :
Wang J
Fu K
Zhang M
Liang L
Ni M
Sun HX
Yin R
Tang M
Source :
Frontiers in oncology [Front Oncol] 2024 May 16; Vol. 14, pp. 1395818. Date of Electronic Publication: 2024 May 16 (Print Publication: 2024).
Publication Year :
2024

Abstract

Introduction: The association between mutations in susceptibility genes and the occurrence of ovarian cancer has been extensively studied. Previous research has primarily concentrated on genes involved in the homologous recombination repair pathway, particularly BRCA1 and BRCA2 . However, a wider range of genes related to the DNA damage response pathways has not been fully explored.<br />Methods: To investigate the mutation characteristics of cancer susceptibility genes in the Chinese ovarian cancer population and the associations between gene mutations and clinical data, this study initially gathered a total of 1171 Chinese ovarian cancer samples and compiled a dataset of germline mutations in 171 genes.<br />Results: In this study, it was determined that MC1R and PRKDC were high-frequency ovarian cancer susceptibility genes in the Chinese population, exhibiting notable distinctions from those in European and American populations; moreover high-frequency mutation genes, such as MC1R : c.359T>C and PRKDC : c.10681T>A, typically had high-frequency mutation sites. Furthermore, we identified c.8187G>T as a characteristic mutation of BRCA2 in the Chinese population, and the CHEK2 mutation was significantly associated with the early onset of ovarian cancer, while the CDH1 and FAM175A mutations were more prevalent in Northeast China. Additionally, Fanconi anemia pathway-related genes were significantly associated with ovarian carcinogenesis.<br />Conclusion: In summary, this research provided fundamental data support for the optimization of ovarian cancer gene screening policies and the determination of treatment, and contributed to the precise intervention and management of patients.<br />Competing Interests: Authors JW, LL, MN and MT are employees of BGI Genomics that produces the panel test used in this study. HS was employed by BGI Research. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.<br /> (Copyright © 2024 Wang, Fu, Zhang, Liang, Ni, Sun, Yin and Tang.)

Details

Language :
English
ISSN :
2234-943X
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
38817903
Full Text :
https://doi.org/10.3389/fonc.2024.1395818